February 17, 2021
The goal of the FY21 LCRP is to eradicate deaths and suffering from lung cancer to better the health and welfare of military Service members, Veterans, and the American public. As such, the LCRP will support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer. Mechanisms include: Career Development Award and Concept Award. Deadlines: April 6 – Pre-application; April 20 - Application
Funding Opportunity: DOD-CDMRP FY21 Lung Cancer Research Program (LCRP)
February 17, 2021
The purpose of this Notice is to announce the intention of NICHD, with NIDCD, NIEHS, NIMH, and NINDS, to issue an FOA to solicit new and renewal applications for autism centers of excellence (ACE) R01 Networks. This FOA will be a reissue of RFA-HD-17-008. A companion FOA will solicit applications for ACE Centers supported by the P50 activity code (see NOT-HD-21-007). An individual may serve as the Principal Investigator for an ACE Center or Network on only one application.
February 17, 2021
The purpose of this Notice of Special Interest (NOSI) is to solicit investigator-initiated applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes.
February 17, 2021
Over the last 2 decades, the suicide rate in the United States has been on a grim, steady march upwards. But a new study highlights an encouraging exception: between 1999 and 2018, the rate of suicide related to cancer decreased. This drop was greatest among people considered to be at higher suicide risk in general, including men and older adults.
February 17, 2021
A new study funded by the National Institutes of Health will evaluate the effects of remdesivir in pregnant women who have been prescribed the drug to treat COVID-19. The study, which will be conducted at 17 sites in the continental United States and Puerto Rico, aims to determine how pregnant women metabolize the drug and whether there are any potential side effects. “Pregnant women with COVID-19 are at high risk for hospitalization, for intensive care admission and for needing ventilator support,” said Diana W. Bianchi, M.D., director of NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). “There is an urgent need to identify effective treatments for this population and to determine whether drugs prescribed for other adults are appropriate for use in pregnancy.”
NIH funds study to evaluate remdesivir for COVID-19 in pregnancy
February 16, 2021
The COVID-19 infection rate among pregnant women was estimated to be 70% higher than in similarly aged adults in Washington state, according to a new study published today in American Journal of Obstetrics and Gynecology.
February 15, 2021
The genetic basis of Lewy body dementia (LBD) is not well understood. Here, we performed whole-genome sequencing in large cohorts of LBD cases and neurologically healthy controls to study the genetic architecture of this understudied form of dementia, and to generate a resource for the scientific community. Genome-wide association analysis identified five independent risk loci, whereas genome-wide gene-aggregation tests implicated mutations in the gene GBA. Genetic risk scores demonstrate that LBD shares risk profiles and pathways with Alzheimer's disease and Parkinson's disease, providing a deeper molecular understanding of the complex genetic architecture of this age-related neurodegenerative condition.
February 14, 2021
White Californians so far have received 32.7% of the first available doses of the COVID-19 vaccine, compared with 16% for Latinos, 13% for Asians, 2.9% for Black people and 0.3% for Native American populations, according to a new state report that provides a snapshot of vaccine distribution.
New state report breaks down vaccine distribution by age, race, gender, and shows disparities
February 12, 2021
Since the pandemic began, cancer researchers have also been contributing their expertise and resources to scientific investigations of the coronavirus. Their findings have been broad in scope, ranging from insights into how the virus enters cells to the identification of potential therapies. For example, cancer researchers reported recently that antibodies to SARS-CoV-2 may protect people from being reinfected by the virus. The research was part of NCI’s ongoing response to the pandemic, which also includes a study of patients with cancer and COVID-19 and studies of genomic factors that influence the severity of the disease.
Cancer Researchers Bring Tools, Experience to COVID-19 Studies
February 11, 2021
Millions of older Americans take aspirin daily to reduce their risk for heart disease and colorectal cancer. But, new data suggests this protective edge for colorectal cancer comes only if they begin taking aspirin before age 70. In a pooled analysis of two large U.S. cohorts of health professionals, researchers confirmed the surprise finding of an earlier clinical trial, known as ASPREE (Aspirin in Reducing Events in the Elderly). That study found regular aspirin use confers no apparent protection against the development of these cancers in an elderly population.
